{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:57:11Z","timestamp":1778651831798,"version":"3.51.4"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2020,7,1]]},"DOI":"10.1001\/jamaophthalmol.2020.1539","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T05:19:00Z","timestamp":1589519940000},"page":"749","source":"Crossref","is-referenced-by-count":32,"title":["Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial"],"prefix":"10.1001","volume":"138","author":[{"given":"Meydan","family":"Ben Ishai","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon","family":"Tiosano","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyal","family":"Fenig","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Davidoff Center for Oncology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Ben Simon","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Goldscgleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iftach","family":"Yassur","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"21","key":"eoi200036r1","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma.","volume":"353","author":"Rubin","year":"2005","journal-title":"N Engl J Med"},{"key":"eoi200036r3","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OTT","article-title":"Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.","volume":"10","author":"Shi","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"7","key":"eoi200036r4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/ceo.12298","article-title":"Histological subtypes of periocular basal cell carcinoma.","volume":"42","author":"Wu","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"eoi200036r5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.joms.2015.09.019","article-title":"Orbital exenteration to manage infiltrative sinonasal, orbital adnexal, and cutaneous malignancies provides acceptable survival outcomes: an institutional review, literature review, and meta-analysis.","volume":"74","author":"Hoffman","year":"2016","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"eoi200036r6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12886-018-0850-y","article-title":"Factors related to survival outcomes following orbital exenteration: a retrospective, comparative, case series.","volume":"18","author":"Aryasit","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"eoi200036r7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrc2503","article-title":"Basal cell carcinomas: attack of the hedgehog.","volume":"8","author":"Epstein","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"eoi200036r8","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"eoi200036r9","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41598-020-58117-0","article-title":"Gene-related response of basal cell carcinoma to biologic treatment with vismodegib.","volume":"10","author":"Sternfeld","year":"2020","journal-title":"Sci Rep"},{"key":"eoi200036r11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ajo.2019.06.027","article-title":"A new paradigm in the treatment of advanced periocular basal cell carcinoma?","volume":"206","author":"Unsworth","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi200036r12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","article-title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.","volume":"18","author":"Dr\u00e9no","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"eoi200036r13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jamadermatol.2016.5058","article-title":"A novel alternate dosing of vismodegib for treatment of patients with advanced basal cell carcinomas.","volume":"153","author":"Becker","year":"2017","journal-title":"JAMA Dermatol"},{"key":"eoi200036r14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9509","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study).","author":"Mortier","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"eoi200036r15","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma.","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"eoi200036r16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.","volume":"72","author":"Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"eoi200036r17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.","volume":"16","author":"Basset-Seguin","year":"2015","journal-title":"Lancet Oncol"},{"key":"eoi200036r18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial.","volume":"86","author":"Basset-S\u00e9guin","year":"2017","journal-title":"Eur J Cancer"},{"issue":"10","key":"eoi200036r19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jamaophthalmol.2013.4430","article-title":"Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.","volume":"131","author":"Kahana","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"eoi200036r20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","article-title":"Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area.","volume":"31","author":"Demirci","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"eoi200036r21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/bjophthalmol-2018-312277","article-title":"Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.","volume":"103","author":"Sagiv","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi200036r22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/IOP.0000000000001166","article-title":"Neoadjuvant vismodegib and Mohs micrographic surgery for locally advanced periocular basal cell carcinoma.","volume":"35","author":"Gonz\u00e1lez","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"eoi200036r23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ajo.2019.04.013","article-title":"Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma.","volume":"207","author":"Eiger-Moscovich","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi200036r24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IOP.0b013e3182831bf3","article-title":"Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.","volume":"29","author":"Yin","year":"2013","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"eoi200036r25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee.","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"eoi200036r27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/aos.2012.90.issue-5","article-title":"Quality of life of eye amputated patients.","volume":"90","author":"Rasmussen","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"eoi200036r28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jech.2003.008466","article-title":"Bias.","volume":"58","author":"Delgado-Rodr\u00edguez","year":"2004","journal-title":"J Epidemiol Community Health"},{"key":"eoi200036r2","unstructured":"American Cancer Society. Key Statistics for Basal and Squamous Cell Skin Cancers. Updated January 8, 2020. Accessed January 8, 2020. https:\/\/www.cancer.org\/cancer\/basal-and-squamous-cell-skin-cancer\/about\/key-statistics.html"},{"key":"eoi200036r10","unstructured":"US Food and Drug Administration. 2012 Notifications. Published February 13, 2018. Accessed July 10, 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/2012-notifications"},{"key":"eoi200036r26","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Published May 28, 2009. Accessed August 15, 2019. https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2765808\/jamaophthalmology_ben_ishai_2020_oi_200036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T15:02:55Z","timestamp":1594306975000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2765808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.1539","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}